TAVR in Patients on Hemodialysis: Outcome of A High-Risk Patient Group

Authors

  • Hendrik Ruge Department of Cardiovascular Surgery, German Heart Center Munich, TUM, Munich, Germany
  • Marcus-André Deutsch linic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center NRW, Bad Oeynhausen, Germany
  • Magdalena Erlebach Department of Cardiovascular Surgery, German Heart Center Munich, TUM, Munich, Germany
  • Melchior Burri Department of Cardiovascular Surgery, German Heart Center Munich, TUM, Munich, Germany
  • Sabine Bleiziffer Clinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center NRW, Bad Oeynhausen, Germany
  • Ruediger Lange Department of Cardiovascular Surgery, German Heart Center Munich, TUM, Munich, Germany

DOI:

https://doi.org/10.1532/hsf.3129

Keywords:

TAVR, hemodialysis

Abstract

Background: Perioperative mortality is high and long-term survival is poor for patients on hemodialysis undergoing surgical aortic valve replacement (SAVR). Transcatheter aortic valve replacement (TAVR) offers a safe and effective therapy for high-risk patients suffering from aortic valve stenosis. However, in patients on hemodialysis only limited information is available on the outcome following TAVR.

Methods: Of the 2613 consecutive patients in our single-center TAVR registry, all hemodialysis patients, were identified. Demographics, procedural details, clinical outcomes, mortality, and complications were evaluated.

Results: Forty-two hemodialysis patients with a mean age of 75.2±8.2 years, a mean STS predicted risk of mortality of 11.1±9.5% and a mean logEuroScore of 27.9±18.8% underwent TAVR. Mean duration on hemodialysis prior to intervention was 62.8±49.6 months. A transfemoral access was chosen in 24 patients, a transapical in 16, and a transaxillary and a transaortic in one patient, respectively. Estimated survival at 30 days, one, three and five years was 83.3%, 68.3%, 37.7% and 18.9%, respectively. Estimated median survival was 1.8±0.4 years. VARC-2 defined perioperative complications included stroke in 7.1% (3/42), major bleeding in 16.7% (7/42), and vascular complications in 7.1% (3/42). In two patients, echocardiographic examination at three and four years, respectively, showed evidence for structural valve deterioration.

Conclusion: A high number of patients with ESRD undergoing TAVR require a non-transfemoral access.
Predominantly, bleeding events contribute to the perioperative morbidity. An estimated median survival of less than two years after TAVR allows only limited assessment of valve prosthesis durability. Cardiovascular and non-cardiovascular mortality contribute equally to the causes of death beyond the first year after TAVR.

References

Allende R, Webb JG, Munoz-Garcia AJ, et al. 2014. Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. European Heart Journal 35:2685-96.

Alqahtani F, Aljohani S, Boobes K, et al. 2017. Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients on Maintenance Dialysis. The American Journal of Medicine 130:1464.e1-1464.e11.

Boning A, Boedeker RH, Rosendahl UP, et al. 2011. Long-term results of mechanical and biological heart valves in dialysis and non-dialysis patients. The Thoracic and Cardiovascular Surgeon 59:454-9.

Capodanno D, Petronio AS, Prendergast B, et al. 2017. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery 52:408-417.

Codner P, Levi A, Gargiulo G, et al. 2016. Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. The American Journal of Cardiology 118:1888-1896.

Conrotto F, Salizzoni S, Andreis A, et al. 2017. Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease. The American Journal of Cardiology 119:1438-1442.

Dumonteil N, van der Boon RM, Tchetche D, et al. 2013. Impact of preoperative chronic kidney disease on short- and long-term outcomes after transcatheter aortic valve implantation: a Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. American Heart Journal 165:752-60.

Ferro CJ, Chue CD, de Belder MA, et al. 2015. Impact of renal function on survival after transcatheter aortic valve implantation (TAVI): an analysis of the UK TAVI registry. Heart 101:546-52.

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. 2013. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382:339-52.

Holmes DR, Jr., Nishimura RA, Grover FL, et al. 2016. Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. The Annals of Thoracic Surgery 101:789-800.

Kappetein AP, Head SJ, Genereux P, et al. 2013. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. The Journal of Thoracic and Cardiovascular Surgery 145:6-23.

Kobrin DM, McCarthy FH, Herrmann HC, et al. 2015. Transcatheter and Surgical Aortic Valve Replacement in Dialysis Patients: A Propensity-Matched Comparison. The Annals of Thoracic Surgery 100:1230-6; discussion 1236-7.

Leon MB, Smith CR, Mack MJ, et al. 2016. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. The New England Journal of Medicine 374:1609-20.

London GM, Pannier B, Marchais SJ, Guerin AP. 2000. Calcification of the aortic valve in the dialyzed patient. Journal of the American Society of Nephrology: JASN 11:778-83.

Mack MJ, Leon MB, Thourani VH, et al. 2019. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. The New England Journal of Medicine.

Ohno Y, Attizzani GF, Barbanti M, et al. 2015. Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis Patients Undergoing Chronic Dialysis. Journal of the American College of Cardiology 66:93-4.

Popma JJ, Deeb GM, Yakubov SJ, et al. 2019. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. The New England Journal of Medicine.

Reardon MJ, Van Mieghem NM, Popma JJ, et al. 2017. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. The New England Journal of Medicine 376:1321-1331.

Ruge H, Burri M, Erlebach M, Lange R. 2020. Access site related vascular complications with third generation transcatheter heart valve systems. Catheterization and Cardiovascular Interventions: Catheter Cardiovasc Interv. 2020;1–8. https://doi.org/10.1002/ccd. 29095.

Szerlip M, Kim RJ, Adeniyi T, et al. 2016. The outcomes of transcatheter aortic valve replacement in a cohort of patients with end-stage renal disease. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography & Interventions 87:1314-21.

Thourani VH, Keeling WB, Sarin EL, et al. 2011. Impact of preoperative renal dysfunction on long-term survival for patients undergoing aortic valve replacement. The Annals of Thoracic Surgery 91:1798-806; discussion 1806-7.

Thourani VH, Sarin EL, Keeling WB, et al. 2011. Long-term survival for patients with preoperative renal failure undergoing bioprosthetic or mechanical valve replacement. The Annals of Thoracic Surgery 91:1127-34.

Urena P, Malergue MC, Goldfarb B, Prieur P, Guedon-Rapoud C, Petrover M. 1999. Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie 20:217-25.

Walther T, Hamm CW, Schuler G, et al. 2015. Perioperative Results and Complications in 15,964 Transcatheter Aortic Valve Replacements: Prospective Data From the GARY Registry. Journal of the American College of Cardiology 65:2173-80.

Williams ML, Bavaria JE, Acker MA, et al. 2016. Valve Selection in End-Stage Renal Disease: Should It Always Be Biological? The Annals of Thoracic Surgery 102:1531-1535.

Published

2020-08-28

How to Cite

Ruge, H., Deutsch, M.-A., Erlebach, M., Burri, M. ., Bleiziffer, S., & Lange, R. (2020). TAVR in Patients on Hemodialysis: Outcome of A High-Risk Patient Group. The Heart Surgery Forum, 23(5), E611-E616. https://doi.org/10.1532/hsf.3129

Issue

Section

Articles

Most read articles by the same author(s)